After the chemotherapy: potential mechanisms for chemotherapy-induced delayed skeletal muscle dysfunction in survivors of acute lymphoblastic leukaemia in childhood

There is evidence that survivors of childhood cancers, such as acute lymphoblastic leukaemia (ALL), have increased rates of longterm skeletal muscle dysfunction. This places them at higher risk of physical restriction and functional impairment as well as potentially contributing to observed increas...

Full description

Bibliographic Details
Main Authors: Celena eScheede-Bergdahl, R Thomas Jagoe
Format: Article
Language:English
Published: Frontiers Media S.A. 2013-04-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fphar.2013.00049/full
_version_ 1831673095229800448
author Celena eScheede-Bergdahl
R Thomas Jagoe
author_facet Celena eScheede-Bergdahl
R Thomas Jagoe
author_sort Celena eScheede-Bergdahl
collection DOAJ
description There is evidence that survivors of childhood cancers, such as acute lymphoblastic leukaemia (ALL), have increased rates of longterm skeletal muscle dysfunction. This places them at higher risk of physical restriction and functional impairment as well as potentially contributing to observed increases in cardiovascular disease and insulin resistance in later life. The mechanisms underlying these changes in skeletal muscle are unknown but chemotherapy drugs used in treatment for ALL are strongly implicated. Normal skeletal muscle growth, development and function are dependent on correctly functioning muscle satellite cells, muscle motor neurons and muscle mitochondria. Each of these key components is potentially susceptible to damage by chemotherapy in childhood, particularly prolonged courses including repeated administration of combination chemotherapy. If this chemotherapy-induced damage is not fully reversible, impairment of satellite cells, muscle motor innervation and mitochondria could, either singly or together, lead to the emergence of delayed or persistent skeletal muscle dysfunction many years later. The known effects of individual drugs used in the treatment of ALL are outlined and the need for specific targeted studies to investigate the mechanisms underlying persistent muscle dysfunction in survivors of childhood cancers is highlighted.
first_indexed 2024-12-20T02:40:19Z
format Article
id doaj.art-5d60401e7c744c02b08209e11848835d
institution Directory Open Access Journal
issn 1663-9812
language English
last_indexed 2024-12-20T02:40:19Z
publishDate 2013-04-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj.art-5d60401e7c744c02b08209e11848835d2022-12-21T19:56:20ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122013-04-01410.3389/fphar.2013.0004943175After the chemotherapy: potential mechanisms for chemotherapy-induced delayed skeletal muscle dysfunction in survivors of acute lymphoblastic leukaemia in childhoodCelena eScheede-Bergdahl0R Thomas Jagoe1McGill UniversityMcGill UniversityThere is evidence that survivors of childhood cancers, such as acute lymphoblastic leukaemia (ALL), have increased rates of longterm skeletal muscle dysfunction. This places them at higher risk of physical restriction and functional impairment as well as potentially contributing to observed increases in cardiovascular disease and insulin resistance in later life. The mechanisms underlying these changes in skeletal muscle are unknown but chemotherapy drugs used in treatment for ALL are strongly implicated. Normal skeletal muscle growth, development and function are dependent on correctly functioning muscle satellite cells, muscle motor neurons and muscle mitochondria. Each of these key components is potentially susceptible to damage by chemotherapy in childhood, particularly prolonged courses including repeated administration of combination chemotherapy. If this chemotherapy-induced damage is not fully reversible, impairment of satellite cells, muscle motor innervation and mitochondria could, either singly or together, lead to the emergence of delayed or persistent skeletal muscle dysfunction many years later. The known effects of individual drugs used in the treatment of ALL are outlined and the need for specific targeted studies to investigate the mechanisms underlying persistent muscle dysfunction in survivors of childhood cancers is highlighted.http://journal.frontiersin.org/Journal/10.3389/fphar.2013.00049/fullMotor Neuronschemotherapyskeletal musclecancer survivorsmuscle dysfunctionmuscle satellite cells
spellingShingle Celena eScheede-Bergdahl
R Thomas Jagoe
After the chemotherapy: potential mechanisms for chemotherapy-induced delayed skeletal muscle dysfunction in survivors of acute lymphoblastic leukaemia in childhood
Frontiers in Pharmacology
Motor Neurons
chemotherapy
skeletal muscle
cancer survivors
muscle dysfunction
muscle satellite cells
title After the chemotherapy: potential mechanisms for chemotherapy-induced delayed skeletal muscle dysfunction in survivors of acute lymphoblastic leukaemia in childhood
title_full After the chemotherapy: potential mechanisms for chemotherapy-induced delayed skeletal muscle dysfunction in survivors of acute lymphoblastic leukaemia in childhood
title_fullStr After the chemotherapy: potential mechanisms for chemotherapy-induced delayed skeletal muscle dysfunction in survivors of acute lymphoblastic leukaemia in childhood
title_full_unstemmed After the chemotherapy: potential mechanisms for chemotherapy-induced delayed skeletal muscle dysfunction in survivors of acute lymphoblastic leukaemia in childhood
title_short After the chemotherapy: potential mechanisms for chemotherapy-induced delayed skeletal muscle dysfunction in survivors of acute lymphoblastic leukaemia in childhood
title_sort after the chemotherapy potential mechanisms for chemotherapy induced delayed skeletal muscle dysfunction in survivors of acute lymphoblastic leukaemia in childhood
topic Motor Neurons
chemotherapy
skeletal muscle
cancer survivors
muscle dysfunction
muscle satellite cells
url http://journal.frontiersin.org/Journal/10.3389/fphar.2013.00049/full
work_keys_str_mv AT celenaescheedebergdahl afterthechemotherapypotentialmechanismsforchemotherapyinduceddelayedskeletalmuscledysfunctioninsurvivorsofacutelymphoblasticleukaemiainchildhood
AT rthomasjagoe afterthechemotherapypotentialmechanismsforchemotherapyinduceddelayedskeletalmuscledysfunctioninsurvivorsofacutelymphoblasticleukaemiainchildhood